US EditionPublished • loading... • Updated
Boehringer-Zealand Drug Leads to 16.6% Weight Loss in Late-Stage Trial
The drug also met key secondary endpoints, including waist circumference reduction, and 85.1% of adults on treatment lost at least 5% of body weight.
- On Tuesday, April 28, 2026, Boehringer Ingelheim and Zealand Pharma announced Phase 3 SYNCHRONIZE-1 results showing survodutide achieved 16.6% average weight loss after 76 weeks, compared to 3.2% for placebo.
- Designed as a dual GLP-1 and glucagon receptor agonist, survodutide aims to decrease appetite while targeting liver fat, positioning it against market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
- Data showed 85.1% of treated patients achieved at least 5% weight reduction versus 38.8% for placebo, with initial analysis indicating weight loss was driven predominantly by fat tissue loss rather than lean mass reduction.
- Shashank Deshpande, Head of Human Pharma at Boehringer Ingelheim, said results "strengthen our confidence in survodutide as a treatment candidate," while Jefferies analyst Benjamin Jackson noted the mechanism is "hoped to translate to better liver targeting for patients with MASH."
- While the drug remains an investigational agent without regulatory approval, Boehringer Ingelheim plans to present full trial data at the American Diabetes Association's 2026 Scientific Sessions in June, with additional results from SYNCHRONIZE and LIVERAGE studies expected later this year.
Insights by Ground AI
15 Articles
15 Articles
Novel GLP-1/glucagon dual agonist confers up to 16.6% weight loss in obesity
A GLP-1/glucagon dual agonist induced up to 16.6% weight loss at 76 weeks for adults with overweight or obesity and without type 2 diabetes, according to topline results from the SYNCHRONIZE-1 trial. Survodutide (Boehringer Ingelheim, Zealand Pharma) is a once-weekly injectable medication currently under investigation for the treatment of overweight or obesity as well as metabolic
Coverage Details
Total News Sources15
Leaning Left4Leaning Right1Center7Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 33%
C 59%
Factuality
To view factuality data please Upgrade to Premium
